No abstract

No abstract

No abstract

The Maltese Megalithic Temples, constructed between the mid-fourth and mid-third millennia BC, are unique and are amongst the oldest stone buildings of such complexity in the world. They are of great local and international significance, embodying symbolic, educational and recreational values. These Temples are currently suffering from a series of severe problems associated with the deterioration of materials as well as structural problems, seen in a number of serious collapses in recent years. In 2000, it was decided that these vulnerable prehistoric structures needed to be protected from the direct impact of environmental factors by means of a temporary, open-sided shelter, conceived as a large parasol designed to be as light as possible, in visual as well as in physical terms. The erection of two of these shelters took place during [2008][2009]. The performance of the shelters is currently being assessed by environmental monitoring which already indicates an improvement in conditions beneath the shelters when compared to conditions on site before sheltering.

Malta, he presently heads the niche area development section at Malta Enterprise.Abstract Malta, with a population of circa 400,000 and no natural resources, has had to exploit every niche business opportunity to enhance its economic prosperity since gaining independence in 1964. In this respect, current endeavours are focused on the generic pharmaceuticals industry. This sector should form the foundation upon which to build a Mediterranean healthcare centre of excellence. This paper explains why generic pharmaceuticals manufacturers locating in Malta within the next few years will have a distinct competitive advantage. Timing holds the key to success in this f|ercely competitive industry. Malta offers a unique blend: the Bolar exemption incorporated into patent legislation; the negligible number of patents registered; and its location between Southern European and North African markets. Together, these bestow the desired timing and attractive marketing opportunities for generics manufacturers.